Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for its ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

In the latest quarter, 7 analysts provided ratings for Eli Lilly LLY +1.30% Get Free Report , showcasing a mix of bullish and ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

A Houston neurologist had his medical license suspended following his arrest on charges that accuse him of soliciting a minor ...

Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in weight-loss and diabetes drugs. With a 32% revenue increase in 2024 and ...

Wall Street Zen downgraded Eli Lilly from a "buy" to a "hold" rating, signaling caution amid a flurry of mixed analyst views. Despite this, Eli Lilly still holds strong support from other firms like ...

Shares of Eli Lilly & Co. LLY slid 2.47% to $775.45 Friday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...